Jami Rubin (EQRx)

Ja­mi Ru­bin, once fa­bled for grilling bio­phar­ma ex­ecs, de­camps to head fi­nance at drug pric­ing dis­rupter

As Gold­man Sachs’ top phar­ma­ceu­ti­cal an­a­lyst, Ja­mi Ru­bin was known for ask­ing the tough ques­tions. Now, as she takes the lead on EQRx’s mis­sion to rewrite the rules of drug pric­ing, we’ll see how good her an­swers are.

Ru­bin made the jump to biotech on April 5, be­com­ing EQRx’s new CFO, the com­pa­ny said Mon­day. She’s com­ing from PJT Part­ners, where she’s been a part­ner pro­vid­ing strate­gic guid­ance for biotech and phar­ma­ceu­ti­cal com­pa­nies for the last cou­ple years. With EQRx’s re­cent $500 mil­lion Se­ries B round in the books, it wouldn’t be a sur­prise if she was al­ready lin­ing up a pub­lic de­but.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.